Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
5 Y5 O, H" @0 R1 t% E3 t. F5 _; j5 Z
; @2 U& Z0 n! h% U7 nSub-category:+ l7 \* Q) [5 L9 l' e
Molecular Targets , T1 a$ n" N& ]+ ?% n) P! m4 a
2 }# c1 H' ?+ G
) g0 f. R! K4 p1 {" P' a/ E0 q% n
Category:( P* N! l# R* k7 T$ K- }
Tumor Biology
! m* y+ s9 e1 O
( K' o8 W7 I& F. X# k4 Y, {! h+ o' |9 a* {: W; v
Meeting:% e$ d# x8 W! Q* _" G f0 B
2011 ASCO Annual Meeting
- P# F1 g+ O F5 I# V: Q c- R" t1 b/ @$ I6 o/ m; V3 C
; m( o) o$ s1 y5 G% A8 W a% ySession Type and Session Title:
( b- R+ Y5 f) f6 P* v3 E3 P+ h% IPoster Discussion Session, Tumor Biology
+ d4 T1 n* ~1 ^6 g. z$ z% ?+ X0 h3 {+ [6 s
+ W3 g; ]- g' }1 p
Abstract No:( P6 V: ~) o. b \# P* T; s
10517 % x& k/ n; j; X9 p! C
5 z' f1 j' g) r, ~1 e
4 r$ D9 i: r- ?# v' HCitation:. @2 ]. K. [ w+ c
J Clin Oncol 29: 2011 (suppl; abstr 10517)
! ~& f/ U ]' ~. D, K9 M1 G$ A1 M9 R& T# u) Y$ M" F
: u, D0 r" _- G/ t7 _ m
Author(s):' c7 W M x' O# Z& K" l
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China + N( M- q, W1 g+ g% }3 h
) J. e8 G5 T4 i# k" n; y* G
( R6 g- ?2 m1 I
- ]5 j* f- K+ D) S, Q: o r, ]Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
9 s; D. C# D6 h* ]* R7 G+ ?3 \+ X( D. G
Abstract Disclosures
0 a. }! `( h% L5 P- | H4 `+ C/ T5 U4 L$ L
Abstract:
% Y) F1 B3 K$ R* B `) c Z$ g8 a
( r+ n. S2 g) F. d8 s+ [1 f
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation. c+ x3 P7 g& K8 _0 _
5 J) T7 ]/ Z# ~8 A7 a4 q& E- t6 [ . `: |, \$ @3 P5 }: V
|
显身卡
